NDA 205029 · Bpi Labs
Epinephrine
Epinephrine · Intramuscular, Intravenous, Subcutaneous, Intravenous, Intravenous, Intraocular, Intramuscular, Subcutaneous · alpha-Adrenergic Agonist; beta-Adrenergic Agonist; Catecholamine
Last checked: Nov 20, 2026Latest source record: Jun 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Jul 29, 2014
Approved uses
3
Original approval plus efficacy supplements
Registered trials
2,347
454 Phase 3, 232 recruiting
FAERS reports
42,335
26,333 serious, 3,545 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 28, 2026.
Epinephrine is a non-selective alpha and beta adrenergic agonist indicated: To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock (1.1) For emergency treatment of allergic reactions (Type 1), including anaphylaxis (1.2) 1.1 Hypotension associated with Septic Shock Epinephrine Injection, USP 1 mg/mL is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. 1.2 Anaphylaxis Emergency treatment of allergic reactions (Type I), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. The signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 11, 2016 Supplement 2 · Efficacy LabelLetter
- Oct 23, 2015 Supplement 1 · Efficacy LabelLetter
- Jul 29, 2014 Original approval · Type 7 - Drug Already Marketed without Approved NDA ReviewLabelLetter
5 products under this application
- EPINEPHRINE · EPINEPHRINE 30MG/30ML (1MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
- EPINEPHRINE · EPINEPHRINE 10MG/10ML (1MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
- EPINEPHRINE · EPINEPHRINE 1MG/ML (1MG/ML) · SOLUTION, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
- EPINEPHRINE · EPINEPHRINE 1MG/ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued
- EPINEPHRINE · EPINEPHRINE 1MG/ML (1MG/ML) · SOLUTION, INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Epinephrine" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- Platform of Randomized Adaptive Clinical Trials in Critical IllnessPivotal-lookingRecruiting
University Health Network, TorontoAcademic, hospital or other
NCT05440851 · 6,250 participants (planned) · Start Apr 30, 2023 · Primary completion Mar 31, 2027
Drug: Early Cohort corticosteroid dose; Extended Cohort corticosteroid dose and 6 more · For: Respiratory Insufficiency; Extracorporeal Membrane Oxygenation Complication; Mechanical Ventilation Pressure High
Sites: Tucson, Arizona; Los Angeles, California; San Diego, California · 103 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19Pivotal-lookingStatus unknown
Huashan HospitalAcademic, hospital or other
NCT05855395 · 5,815 participants (planned) · Start May 26, 2023 · Primary completion May 1, 2024
Drug: Glucocorticoid · For: COVID-19
Sites: Fuzhou, China; Quanzhou, China; Guangzhou, China · 15 sites in all
- Impact of Low Dose Epinephrine in the Management of Out-of-hospital Cardiac Arrest on Neurological OutcomePivotal-lookingNot yet recruiting
Central Hospital, Nancy, FranceAcademic, hospital or other
NCT07442071 · 4,336 participants (planned) · Start Jun 2026 · Primary completion Jul 2030
Drug: Epinephrine 0.5 mg intravenous bolus; Epinephrine 1 mg intravenous bolus · For: Out-of-hospital Cardiac Arrest (OHCA)
Sites: Annecy, France; Bayonne, France; Besançon, France · 26 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective4,536
- headache3,074
- sinusitis2,919
- fatigue2,801
- product dose omission issue2,780
- pain2,488
- covid-192,424
- dyspnoea2,269
- nausea2,230
- pneumonia2,076
- off label use2,065
- inappropriate schedule of product administration1,785
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 133 |
| 2005 | 118 |
| 2006 | 136 |
| 2007 | 166 |
| 2008 | 194 |
| 2009 | 269 |
| 2010 | 261 |
| 2011 | 702 |
| 2012 | 425 |
| 2013 | 301 |
| 2014 | 411 |
| 2015 | 635 |
| 2016 | 1,057 |
| 2017 | 1,572 |
| 2018 | 2,477 |
| 2019 | 3,337 |
| 2020 | 6,460 |
| 2021 | 3,909 |
| 2022 | 3,582 |
| 2023 | 3,781 |
| 2024 | 4,431 |
| 2025 | 4,735 |
| 2026 | 3,240 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Epinephrine (Epinephrine)
2024 spending
$119M
Beneficiaries
458,644
578,447 claims
Per beneficiary
$260
$99.63 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $94,680,100 |
| 2021 | $121,105,229 |
| 2022 | $116,328,376 |
| 2023 | $133,365,359 |
| 2024 | $119,280,229 |
Part B: Epinephrine (Epinephrine HCL/PF) · HCPCS J0173
2024 spending
$28K
Beneficiaries
1,177
1,251 claims
Per beneficiary
$24
2024 ASP limit $1.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $28,242 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis.
Shaker MS, Wallace DV, Golden DBK, et al. · J Allergy Clin Immunol 2020 · Meta-Analysis, Systematic Review
- Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.
Levy B, Clere-Jehl R, Legras A, et al. · J Am Coll Cardiol 2018 · Comparative Study, Multicenter Study
- A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest.
Perkins GD, Ji C, Deakin CD, et al. · N Engl J Med 2018 · Multicenter Study, Randomized Controlled Trial
- Pharmacokinetics/pharmacodynamics of epinephrine after single and repeat administration of neffy, EpiPen, and manual intramuscular injection.
Casale TB, Ellis AK, Nowak-Wegrzyn A, et al. · J Allergy Clin Immunol 2023 · Randomized Controlled Trial, Clinical Trial, Phase I
- Epinephrine for bronchiolitis.
Hartling L, Bialy LM, Vandermeer B, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
- Epinephrine absorption in adults: intramuscular versus subcutaneous injection.
Simons FE, Gu X, Simons KJ · J Allergy Clin Immunol 2001 · Clinical Trial, Randomized Controlled Trial
Sponsor: Bpi Labs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.